bs-20372R [Primary Antibody]
CHRM4 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CHRM4

Immunogen Range: 131-230/479


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1132

Swiss Prot: P08173

Source: KLH conjugated synthetic peptide derived from human CHRM4

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine to these receptors and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and postassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The clinical implications of this receptor are unknown; however, mouse studies link its function to adenylyl cyclase inhibition. Muscarinic acetylcholine receptor M4 has been reported to be expressed in many regions of the rat brain, particularly the striatum and hippocampus.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 53


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

U251 lysates probed with CHRM4 Polyclonal Antibody, Unconjugated (bs-20372R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Lane 1: Human U-2 OS cell lysates; Lane 2: Human THP-1 cell lysates; Lane 3: Human MCF-7 cell lysates; Lane 4: Human A549 cell lysates probed with CHRM4 Polyclonal Antibody, Unconjugated (bs-20372R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.